Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy

Current Gene Therapy

Volumn 14, Issue 4, 2014, Pages 289-299

  Yang, Zhenzhen ^a   Xiang, Bai ^a   Dong, Dawen ^a   Wang, Zhanzhang ^a   Li, Jingquan ^a   Qi, Xianrong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Angiopep; Anti angiogenesis; Dual modified liposomes; Glioma; tLyP 1; VEGF siRNA

Indexed keywords

ALPHA INTERFERON; ANGIOPEP; CELL PENETRATING PEPTIDE; INTERLEUKIN 6; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUROPILIN 1; SMALL INTERFERING RNA; TLYP 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; AMINO ACID SEQUENCE; ANIMAL; DRUG EFFECTS; DRUG SCREENING; ENDOSOME; GENE THERAPY; GENE VECTOR; GENETICS; GLIOMA; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULAR GENETICS; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; PROCEDURES; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; ENDOSOMES; GENE SILENCING; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNITY, INNATE; LIPOSOMES; MALE; MICE, NUDE; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907154973     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140612151726     Document Type: Article

References (44)

1. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10(5): 319-31.
2. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009; 6(11): 648-57.
3. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2(2): 91-100.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
5. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9(6); 685-93.
6. Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007; 104(3): 768-78.
7. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359(6398): 845-8.
8. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Del Rev 2007; 59(2-3): 75-86.
9. Bhavsar D, Subramanian K, Sethuraman S, Krishnan UM. Translational siRNA therapeutics using liposomal carriers: prospects & challenges. Curr Gene Ther 2012; 12(4) 315-32.
10. Gurudevan S, Kanwar RK, Veedu RN, et al. Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer. Curr Gene Ther 2013; 13(5): 322-34.
11. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 2010; 18(4): 828-34.
12. Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann NY Acad Sci 2006; 1082: 1-8.
13. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007; 24(9): 1759-71.
14. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27(5): 909-18.
15. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000; 60(8): 2300-3.
16. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 1997; 57(13): 2799-805.
17. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the lowdensity lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008; 106(4): 1534-44.
18. Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008; 324(3): 1064-72.
19. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Antiglioblastoma efficacy and safety of paclitaxel-loading Angiopepconjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012; 33(32): 8167-76.
20. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 2009; 106(38): 16157-62.
21. Osada H, Tokunaga T, Nishi M, et al. Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. Anticancer Res 2004; 24(2B): 547-52.
22. Roth L, Agemy L, Kotamraju VR, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2011; 31(33): 3754-63.
23. Xin H, Jiang X, Gu J, et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dualtargeting drug delivery system for brain glioma. Biomaterials 2011; 32(18): 4293-305.
24. Xiang B, Dong DW, Shi NQ, et al. PSA-responsive and PSMAmediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 2013; 34(28): 6976-91.
25. Dong DW, Xiang B, Gao W, Yang ZZ, Li JQ, Qi XR. pHresponsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials 2013; 34(20): 4849-59.
26. Gao W, Xiang B, Meng TT, Liu F, Qi XR. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 2013; 34(16): 4137-49.
27. Zhao ZX, Gao SY, Wang JC, et al. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 2012; 33(28): 6793-807.
28. Tong SW, Xiang B, Dong DW, Qi XR. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012; 434(1-2): 413-9.
29. Zhao JH, Zhu BD, Huang Q, Wang P, Qi GH. Effects of sheng-Yu decoction on bone marrow, cell cycle and apoptosis of myelosuppressed mice. Chin J Exp Trad Med Formul 2011; 17: 199-202.
30. Buyens K, de Smedt SC, Braeckmans K, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release 2012; 158(3): 362-70.
31. Buyens K, Demeester J, de Smedt SS, Sanders NN. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes. Langmuir 2009; 25(9): 4886-91.
32. Sou K, Endo T, Takeoka S, Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 2000; 11(3): 372-9.
33. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
34. Price ME, Cornelius RM, Brash JL. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochimica et Biophysica Acta 2001; 1512(2): 191-205.
35. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011; 63(3): 161-9.
36. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 33(29): 7138-50.
37. Liu J, Kopeckova P, Buhler P, et al. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm 2009; 6(3): 959-70.
38. Stuart AD, Brown TD. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J Virol 2006; 80(15): 7500-9.
39. Xu Y, Szoka FC, Jr., Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35(18): 5616-23.
40. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
41. Berz D, Wanebo H. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. J Surg Oncol 2012; 103(6): 574-86.
42. T Persigehl, J Ring, T Budny, et al. Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy. Mol Imag 2013; 12(7): 1-11.
43. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19(2): 89-102.
44. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23(4): 457-62.